Latest Development Programs News

Australian Oil Company (ASX:AOK) is ramping up activity in Queensland's Surat Basin, engaging Energetica Consulting for independent resource assessments and pushing production restarts at Emu Apple and Riverslea fields.

Krakatoa Resources (ASX: KTA) has raised $1.6 million through a placement to fund its 2026 drilling and development program at the Zopkhito Antimony-Gold Project. The capital will support efforts to convert a foreign resource estimate into a JORC-compliant Mineral Resource Estimate, alongside metallurgical and environmental studies.

Venus Metals Corporation has secured $47 million from selling its Youanmi Gold Project royalty, while exploration at Henderson and Youanmi Base Metals projects reveals promising targets. The company also initiates titanium extraction R&D and plans special dividends for shareholders.

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.

Orbminco Limited's latest infill drilling at Majestic North delivers standout shallow gold grades, setting the stage for a resource upgrade and advancing mining studies.

Provaris Energy has raised $1 million through a share placement to fund key 2026 development milestones in hydrogen and liquid CO2 storage, reinforcing its technical progress and partnerships.

Simble Solutions edges closer to $1 million in annual recurring revenue as major customer rollouts advance and its NanoSensor program moves forward along a structured development pathway.

Felix Gold has created Frontier Antimony Refinery Corp., a US-focused refining platform with secured access to military-grade antimony ore from its Treasure Creek Project in Alaska, aiming to address critical supply gaps.

Simble Solutions is on the cusp of revealing initial results from its NanoSensor technology development, targeting major markets including Industrial IoT, defence sensing, and wearable medical devices.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

VEEM Limited has finished its factory extension and installed new machinery, setting the stage for a stronger second half of FY26 and anticipated growth in FY27 driven by defence contracts and marine propulsion innovations.